CTSA COVID-19 Funding Opportunities

NOT-TR-20-015 - Notice of NCATS' Participation in PA-18-935 "Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)"

Notice Number: NOT-TR-20-015

The purpose of this Notice is to inform applicants that the National Center for Advancing Translational Sciences (NCATS) will participate, effective immediately, in PA-18-935 “Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement – Clinical Trial Optional)”.

More Information

07/10/2020 - 07/09/2021 NOT-TR-20-011: Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Heath Need

Notice Number: NOT-TR-20-011

National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel Coronavirus (COVID-19). NCATS is particularly interested in projects focusing on the use of informatics solutions to diagnose cases and the use of CTSA-supported core resources (e.g., advanced scientific instruments, highly-specialized facilities, and regulatory expertise) to facilitate research on COVID-19 and advance the translation of research findings into diagnostics, therapeutics, and vaccines.

First Available Due Date: May 04, 2020
Application and Submission Information is in the NOSI please review the appropriate dates:

Activity Codes

FOA Title

Applicable Dates

UL1, U01, R21 PA-18-591 – Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) Applicable Receipt Dates:

  • May 4, 2020
  • November 2, 2020
U01 PAR-19-099 – Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative Innovation Award (U01 Clinical Trial Optional) Applicable Receipt Dates:

  • July 10, 2020
  • November 9, 2020
  • March 8, 2021
  • July 9, 2021
R21 PAR-19-100 – Limited Competition: Clinical and Translational Science Award (CTSA) Program: Exploratory Collaborative Innovation Awards (R21 Clinical Trial Optional) Applicable Receipt Dates:

  • July 10, 2020
  • November 9, 2020
  • March 8, 2021
  • July 9, 2021
UL1 PAR-19-337 – Limited Competition: Competitive Revision Awards for the Clinical and Translational Science Award (CTSA) Program (U54 Clinical Trial Optional). Applicable Receipt Date:

  • September 25, 2020

You must apply to the appropriate Funding Opportunity Announcement and include the NOSI #. Please read the NOSI for complete information.

More Information

NOT-TR-20-018 -Notice of Change in Eligibility and Activity Codes for NOT-TR-20-011, Notice of Special Interest (NOSI): Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Heath Need

Notice Number: NOT-TR-20-018

National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel Coronavirus (COVID-19). NCATS is particularly interested in projects focusing on the use of informatics solutions to diagnose cases and the use of CTSA-supported core resources (e.g., advanced scientific instruments, highly-specialized facilities, and regulatory expertise) to facilitate research on COVID-19 and advance the translation of research findings into diagnostics, therapeutics, and vaccines. NCATS is soliciting applications for Administrative Supplements to UL1, U01, and R21 awards (through PA-18-591), Collaborative Innovation Awards to U01 and R21 awards (through PAR-19-099 and PAR-19-100, respectively), and Competitive Revisions for UL1 awards for each of the non-administrative supplement awards (through PAR-19-337).

Application and Submission Information

Activity Codes

FOA Title

Applicable Dates

UL1, U01, R21

PA-18-591 – Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

Applicable Receipt Dates:

  • May 4, 2020
  • November 2, 2020

U01

PAR-19-099 – Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative Innovation Award (U01 Clinical Trial Optional)

Applicable Receipt Dates:

  • July 10, 2020
  • November 9, 2020
  • March 8, 2021
  • July 9, 2021

R21

PAR-19-100 – Limited Competition: Clinical and Translational Science Award (CTSA) Program: Exploratory Collaborative Innovation Awards (R21 Clinical Trial Optional)

Applicable Receipt Dates:

  • July 10, 2020
  • November 9, 2020
  • March 8, 2021
  • July 9, 2021

UL1

PAR-19-337 – Limited Competition: Competitive Revision Awards for the Clinical and Translational Science Award (CTSA) Program (U54 Clinical Trial Optional).

Applicable Receipt Date:

  • September 25, 2020
Release Date: April 27, 2020
First Available Due Date: Please review tables above
Expiration Date: November 11, 2020

 You must apply to the appropriate Funding Opportunity Announcement and include the NOSI #. Please read the NOSI for complete information.

More Information

08/07/2020 - NOT-OD-20-121: Notice of Special Interest (NOSI): Limited Competition for Emergency Competitive Revisions for Community-Engaged Research on COVID-19 Testing among Underserved and/or Vulnerable Populations

Notice Number: NOT-OD-20-121

This Notice of Special Interest (NOSI) highlights the urgent need to understand and address COVID-19 morbidity and mortality disparities among underserved and vulnerable populations across the United States. These two-year community-engaged Testing Research Projects will examine SARS-CoV-2 infection patterns and efforts to increase access and effectiveness of diagnostic methods through the Rapid Acceleration of Diagnostics for Underserved Populations (RADx-UP) initiative. The overarching goal is to understand factors that have led to disproportionate burden of the pandemic on these underserved populations so that interventions can be implemented to decrease these disparities. The funding for this supplement program is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

The Office of the Director (OD) is therefore offering Emergency Competitive Revisions to active eligible grants and cooperative agreements addressing the objectives described below. This NOSI is one of four related RADx-UP funding opportunities. This Testing Research Projects NOSI will support supplements to NIH grantees that are part of large-scale networks, consortia, centers and other current programs that have adequate capacity, infrastructure, and established community-engaged relationships to support large-scale testing.

Release Date: June 12, 2020
First Available Due Date: August 07, 2020
Expiration Date: August 08, 2020

You must apply to the appropriate Funding Opportunity Announcement and include the NOSI #. Please read the NOSI for complete information.

More Information

09/08/2020 - NOT-OD-20-119 - Notice of Special Interest (NOSI): Emergency Competitive Revisions for Social, Ethical, and Behavioral Implications (SEBI) Research on COVID-19 Testing among Underserved and/or Vulnerable Populations

Notice Number: NOT-OD-20-119

This Notice of Special Interest (NOSI) highlights the urgent need to understand the social, ethical, and behavioral implications (SEBI) of COVID-19 testing among underserved and/or vulnerable populations across the United States through the Rapid Acceleration of Diagnostics for Underserved Populations (RADx-UP) initiative. The overarching goal is to understand factors that have led to disproportionate burden of the pandemic on these underserved populations so that interventions can be implemented to decrease these disparities. The funding for this supplement is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

The Office of the Director is therefore offering Emergency Competitive Revisions to active eligible grants and cooperative agreements addressing the objectives described below. This NOSI is one of four related RADx-UP opportunities. The purpose of this SEBI NOSI is to identify, analyze, and address the social, ethical, and behavioral factors likely to influence access and uptake of COVID-19 testing in underserved and/or vulnerable populations. Single or mixed methods approaches involving community partners will inform the development and evaluation of such testing programs. These studies will assess the ethical, historical, healthcare, social and contextual factors surrounding COVID-19 testing, as well as how cultural beliefs and attitudes, perceived expectations, and preferences influence the ability and willingness to get tested and participate in follow-up evaluations. Findings will be used to develop interventions to mitigate barriers to access and increase uptake of testing. Studies focused on unintended consequences of COVID-19 testing in these groups are also of interest when related to social and ethical issues.

Release Date: June 12, 2020
First Available Due Date: July 08, 2020
Expiration Date: September 09, 2020

You must apply to the appropriate Funding Opportunity Announcement and include the NOSI #. Please read the NOSI for complete information.

More Information

09/08/2020 - NOT-OD-20-120: Notice of Special Interest (NOSI): Emergency Competitive Revisions for Community-Engaged Research on COVID-19 Testing among Underserved and/or Vulnerable Populations

Notice Number: NOT-OD-20-120

This Notice of Special Interest (NOSI) highlights the urgent need to understand and address COVID-19 morbidity and mortality disparities among underserved and vulnerable populations across the United States. These two-year community-engaged Testing Research Projects will examine SARS-CoV-2 infection patterns and efforts to increase access and effectiveness of diagnostic methods through the Rapid Acceleration of Diagnostics for Underserved Populations (RADx-UP) initiative. The overarching goal is to understand factors that have led to disproportionate burden of the pandemic on these underserved populations so that interventions can be implemented to decrease these disparities. The funding for this supplement program is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

The Office of the Director (OD) is therefore offering Emergency Competitive Revisions to active eligible grants and cooperative agreements addressing the objectives described below. This NOSI is one of four related RADx-UP funding opportunities. This Testing Research Projects NOSI will support supplements to individual NIH research awards that include community collaborations or partnerships to support COVID-19 testing (or have the capacity to ramp up quickly) to reach underserved and/or COVID-19 vulnerable populations.

Release Date: June 12, 2020
First Available Due Date: July 08, 2020
Expiration Date: September 09, 2020

You must apply to the appropriate Funding Opportunity Announcement and include the NOSI #. Please read the NOSI for complete information.

More Information

10/16/2020 - NOT-TR-20-012: Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19)

Notice Number: NOT-TR-20-012

National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel coronavirus (SARS-CoV-2) and the disease it causes, i.e., “coronavirus disease 2019” (COVID-19). NCATS is particularly interested in projects that repurpose existing drugs or biologics (existing therapeutics) that have already begun or completed a Phase I clinical trial.

First Available Due Date: June 05, 2020
Expiration Date: October 17, 2020

You must apply to the appropriate Funding Opportunity Announcement and include the NOSI #. Please read the NOSI for complete information.

More Information

11/10/2020 - NOT-TR-20-028 - Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions and Administrative Supplements to Clinical and Translational Science Award (CTSA) Program Awards to Address 2019 Novel Coronavirus Disease (COVID-19) Public Health Needs

Notice Number: NOT-TR-20-028

The National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for projects that address the COVID-19 Public Health Emergency. The Clinical and Translational Science Award (CTSA) Program is uniquely qualified to contribute to these efforts. NCATS is soliciting applications for Administrative Supplements (through PA-18-591) and Emergency Competitive Revisions (through PA-20-135) from current Clinical and Translational Science Award (CTSA) UL1 and U24 award recipients as follows:

Release Date: April 23, 2020
First Available Due Date: May 04, 2020
Expiration Date: November 11, 2020

You must apply to the appropriate Funding Opportunity Announcement and include the NOSI #. Please read the NOSI for complete information.

More Information

11/10/2020 - NOT-TR-20-029 - Notice of Special Interest (NOSI): New Administrative Supplement Applications to UL1 and U24 CTSA Awards to Address COVID-19 Public Heath Need

Notice Number: NOT-TR-20-029

The National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the need for projects that address the coronavirus disease 2019 (COVID-19) Public Health Emergency. The Clinical and Translational Science Award (CTSA) Program is uniquely qualified to contribute to these efforts. NCATS is soliciting applications for Administrative Supplements (through PA-18-591) from current Clinical and Translational Science Award (CTSA) UL1 and U24 award recipients as follows:

FOA

Responsive Activity

Expected Number of Awards

RFA-TR-17-006 CTSA Program Data to Health (CD2H) Coordinating Center (U24)

Digital health platforms and models that integrate data, assess risk, and provide illness/infection surveillance, management tools, and inform clinical practice

1

RFA-TR-15-002 CTSA Network – Trial Innovation Centers (TICs) (U24)

RFA-TR-15-004 Clinical and Translational Science Award (CTSA) Network Recruitment Innovation Centers (RICs) (U24)

Planning of COVID-19 trials; additional recruitment and retention support; eConsent support; and provision of a platform and statistical expertise to collect and perform meta-analyses of COVID-19 therapeutic trials; collection and analysis of COVID-19 health records

1-2

UL1 Components Only

PAR-18-940 Clinical and Translational Science Award (U54 Clinical Trial Optional)

PAR-18-464 Clinical and Translational Science Award (U54 Clinical Trial Optional)

PAR-15-304 Clinical and Translational Science Award (U54 Clinical Trial Optional)

RFA-TR-14-009 Clinical and Translational Science Award (U54 Clinical Trial Optional)

Support of the NCATS National COVID Cohort Collaborative (N3C): Provision of clinical data in specified formats to support illness/infection status/surveillance determinations and/or clinical study data (awards anticipated to be $50,000 to $100,000 Total Costs)

5-10

Use of informatics solutions to diagnose cases

1-5

Use of CTSA-supported core resources (e.g., advanced scientific instruments, highly-specialized facilities, and regulatory expertise) to facilitate research on COVID-19 and advance the translation of research findings into diagnostics, therapeutics, and vaccines

1-5

 

Release Date: June 15, 2020
First Available Due Date: November 10, 2020
Expiration Date: November 11, 2020

 You must apply to the appropriate Funding Opportunity Announcement and include the NOSI #. Please read the NOSI for complete information.

More Information

12/02/2020 - PAR-20-237 - Community Interventions to Address the Consequences of the COVID-19 Pandemic among Health Disparity and Vulnerable Populations (R01- Clinical Trial Optional)

Notice Number: PAR-20-237

This Funding Opportunity Announcement (FOA) encourages applications to implement and evaluate community interventions testing 1) the impacts of mitigation strategies to prevent COVID-19 transmission in NIH-designated health disparity populations and other vulnerable groups; and 2) already implemented, new, or adapted interventions to address the adverse psychosocial, behavioral, and socioeconomic consequences of the pandemic on the health of these groups.

Release Date: June 17, 2020

Open Date: (Earliest Submission Date) July 28, 2020
Application Due Date: (s) August 28, 2020; December 1, 2020
Expiration Date: December 02, 2020

 You must apply to the appropriate Funding Opportunity Announcement and include the PAR#. Please read the PAR for complete information.

More Information

12/15/2020 - NOT-MH-20-053 - Notice of Special Interest (NOSI): Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19

Notice Number: NOT-MH-20-053

This Notice of Special Interest (NOSI) highlights interest in research to strengthen the healthcare response to Coronavirus Disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and to future public health emergencies, including pandemics. While the direct clinical effects of COVID-19 are supported by other funding opportunities, the purpose of this NOSI is to support research to address secondary health effects of the social, behavioral, and economic changes, particularly among populations who experience health disparities and vulnerable populations through the use of digital health assessments and interventions to yield measurable near-term impact.

Release Date: June 5, 2020
First Available Due Date: June 10, 2020
Expiration Date: December 30, 2020

You must apply to the appropriate Funding Opportunity Announcement and include the NOSI #. Please read the NOSI for complete information.

More Information

03/02/2021 - PAR-20-243 - Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19 (R01 - Clinical Trial Optional)

Notice Number: PAR-20-243

This funding opportunity announcement aims to support research to strengthen the healthcare response to Coronavirus Disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and to future public health emergencies, including pandemics. While the direct clinical effects of COVID-19 are studied elsewhere, the pandemic has social, behavioral, and economic impacts on a wide range of health conditions. Thepurpose of this research is to focus on the role and impact of digital health interventions to address access, reach, delivery, effectiveness, scalability and sustainability, particularly in populations who experience health disparities and vulnerable populations.

Posted Date: June 26, 2020
Open Date (Earliest Submission Date):  July 20, 2020
Letter of Intent Due Date(s): Not Applicable
Application Due Date(s): August 20, 2020, December 2, 2020, March 2, 2021

You must apply to the appropriate Funding Opportunity Announcement and include the PAR #. Please read the PAR for complete information.

More Information

07/13/2021 - NOT-OD-20-129 - Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19) in Individuals with Down Syndrome for the INCLUDE Project

Notice Number: NOT-OD-20-129

NIH is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) in individuals with Down syndrome in conjunction with the INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) Project. Because many people with Down syndrome are at increased risk of having co-occurring medical conditions, such as pulmonary disease, cardiac problems, obesity, diabetes, sleep apnea, and altered immune function that may predispose them to more severe infection with SARS-CoV-2, they may be particularly vulnerable to COVID-19 complications. Combined with shared living situations, and reduced access to testing and treatment services due to disparities in provision of resources, the impact of COVID-19 infection in people with Down syndrome is likely to be elevated. The overarching goal of this NOSI is to improve understanding and treatment of COVID-19 infection in individuals with Down syndrome and reduce COVID-19 associated morbidity and mortality for this population, which may be disproportionately affected by, have higher infection rates of, and/or be at elevated risk for adverse outcomes from contracting the virus.

Release Date: June 25, 2020
First Available Due Date: July 13, 2020
Expiration Date: July 13, 2021

You must apply to the appropriate Funding Opportunity Announcement and include the NOSI #. Please read the NOSI for complete information.

More Information

GCO Funding Opportunities

Monthly and continuous submission funding opportunity packets are available on the GCO Funding Opportunities web page.

STAY CONNECTED

Sign up for the Research Listserv to stay up to date with the latest news and events.